Sowell Financial Services’s Ligand Pharmaceuticals LGND Stock Holding History

Sowell Financial Services’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$489K	Buy	1,547 +31	+2%	+$7.3K	0.02%	661
2026 Q1	$303K	Buy	1,516 +188	+14%	+$37.2K	0.01%	832
2025 Q4	$251K	Buy	+1,328	New	+$255K	0.01%	905
2020 Q4	–	Sell	-18	Closed	-$1K	–	2787
2020 Q3	$1K	Sell	18 -11	-38%	-$751	﹤0.01%	2393
2020 Q2	$2K	Sell	29 -86	-75%	-$5.45K	﹤0.01%	2174
2020 Q1	$5K	Sell	115 -108	-48%	-$6.12K	﹤0.01%	1821
2019 Q4	$14K	Sell	223 -5	-2%	-$334	﹤0.01%	1566
2019 Q3	$14K	Buy	+228	New	+$14.3K	﹤0.01%	1412

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sowell Financial Services's LGND Position: Q2 2026 in Review

Sowell Financial Services increased its Ligand Pharmaceuticals (LGND) stake by 2% in Q2 2026, buying an estimated $7.3K and bringing the position to 1,547 shares worth $489K. The position accounts for 0.02% of the portfolio, ranked #661.

Sowell Financial Services first reported a position in LGND in Q3 2019 and has held it in 8 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Sowell Financial Services held 1,547 shares of Ligand Pharmaceuticals worth $489K as of Q2 2026.
Sowell Financial Services bought 31 Ligand Pharmaceuticals shares in Q2 2026, an estimated $7.3K.
Ligand Pharmaceuticals made up 0.02% of Sowell Financial Services's portfolio in Q2 2026, its #661 holding.
Sowell Financial Services first reported a position in Ligand Pharmaceuticals in Q3 2019 and has held it in 8 quarters since.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Sowell Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.